FDA Inspection 997053 — Avanti Polar Lipids

Avanti Polar Lipids — FEI 1036868

The FDA completed an inspection of Avanti Polar Lipids on November 14, 2016 in Alabaster, AL. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 7 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
November 14, 2016
Fiscal Year
2017
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Alabaster, AL (United States)

Citations

IDCFRDescription
104921 CFR 211.22(a)Approve or reject components, products
110521 CFR 211.22(d)Procedures not in writing, fully followed
142021 CFR 211.42(c)(9)Control / Lab Operations Area
179021 CFR 211.80(b)Handling and Storage to Prevent Contamination
358521 CFR 211.110(a)Control procedures to monitor and validate performance
430621 CFR 211.80(a)Written Procedures Not Followed
447921 CFR 108.25(e)Recall procedures